A Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy Phase II Trial to Evaluate the Efficacy and Safety of the Combinations of Lercanidipine and Valsartan in Comparison to Each Component Administered Alone and to Determine the Optimal Dose Combinations in Patients With Essential Hypertension.
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2014
At a glance
- Drugs Lercanidipine/valsartan (Primary) ; Lercanidipine; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors LG Life Sciences
- 17 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2010 New trial record